India’s Food Regulator Challenges a GLP-1 Protein Drink From Dr Reddy’s and Nestle Health Science
FSSAI has issued show-cause notices over Celevida GLP+, flagging claims about preserving lean muscle during GLP-1 therapy. Amazon, Flipkart and Netmeds were also served.
Nutrition products built for people on GLP-1 drugs are multiplying. In India, the food regulator is now asking whether one of them crossed the line.
TLDR
- The Food Safety and Standards Authority of India (FSSAI) issued show-cause notices over Celevida GLP+.
- The product comes from a joint venture between Dr Reddy’s and Nestle Health Science.
- FSSAI flagged claims about preserving lean muscle during GLP-1 therapy.
- Sellers Amazon, Flipkart and Netmeds also received notices.
Who Received Notices
According to Business Standard and Storyboard18, notices went to Dr Reddy’s Laboratories, Nestle Health Science, Tirupati Wellness, Flipkart, Amazon Seller Services and Netmeds. A show-cause notice asks a company to explain why regulatory action should not be taken.
The Claims in Question
FSSAI objected to claims including “High protein support for lean muscle preservation during GLP-1/GIP therapies,” “Help Maintain Lean Muscle,” “support muscle strength” and “preserves lean mass.”
The regulator also called the phrases “Imported from Europe for purity” and “complete daily nourishment” ambiguous. It said the product name itself could create a misleading link to GLP-1 drugs, and that the product’s disclaimer was not enough to fix that.
Why It Matters
Muscle loss during GLP-1 treatment is a real concern, and protein is the obvious food answer. That has made “GLP-1 friendly” one of the hottest labels in nutrition. India’s action shows regulators are starting to test whether a food can borrow a drug’s name and promise a health outcome. Brands selling GLP-1 companion products in other markets will be watching.
Sources: Business Standard; Storyboard18.